EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
EyePoint Pharmaceuticals shares opened down approximately 70% after the Company disclosed that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO trial. Levi & Korsinsky is investigating on behalf of EYPT investors who lost money. NEW YORK, Aug. 26, 2026 /PRNewswire/...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.